SCHEMBL4539658

SCHEMBL4539658

Clc1ncnc2c1oc1ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 1.00
ALDH1A1 P00352 9/20 0.67
LMNA P02545 4/20 0.67
KMT2A Q03164 4/20 0.67
LIMK1 P53667 1/20 0.67
GPR55 Q9Y2T6 1/20 0.67
MAPT P10636 3/20 0.61
HPGD P15428 7/20 0.59
NPC1 O15118 4/20 0.59
RAB9A P51151 4/20 0.59
TSHR P16473 3/20 0.58
HSD17B10 Q99714 3/20 0.58
KDM4E B2RXH2 3/20 0.58
CASP3 P42574 2/20 0.58
SENP7 Q9BQF6 2/20 0.58
PPARG P37231 2/20 0.58
NCOA1 Q15788 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
NCOA2 Q15596 1/20 0.58
MEN1 O00255 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29989707 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1LMNAKMT2ALIMK1
SCHEMBL27164742 0.86 SMN1; SMN2 (0.74) SMN1; SMN2ALDH1A1LMNAKMT2ALIMK1
SCHEMBL25485328 0.81 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1LMNAKMT2ALIMK1
SCHEMBL23610616 0.80 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1LMNAKMT2ALIMK1
SCHEMBL4594832 0.80 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1LMNAKMT2AGPR55
SCHEMBL16406269 0.80 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1LMNAKMT2ALIMK1
SCHEMBL22872914 0.80 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1LMNAKMT2ALIMK1
SCHEMBL4436186 0.80 LIMK1 (1.00) SMN1; SMN2ALDH1A1LMNAKMT2ALIMK1
SCHEMBL20502082 0.80 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1LMNAKMT2ALIMK1
SCHEMBL30080988 0.80 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1LMNAKMT2ALIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3630759-B1 COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER CENTRE NAT RECH SCIENT (FR) 2024-05-01 EP disclosed
US-11932638-B2 Ion channel inhibitor compounds for cancer treatment CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) 2024-03-19 US disclosed
EP-4061818-B1 MACROCYCLIC PEPTIDES AS PD-L1 INHIBITORS AND IMMUNOMODULATORS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES BRISTOL MYERS SQUIBB CO (US) 2023-12-06 EP disclosed
US-20230269954-A1 Light-Emitting Element, Display Device, Electronic Device, and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO. LTD. (JP) 2023-08-24 US disclosed
US-20230210005-A1 Light-Emitting Element, Compound, Organic Compound, Display Module, Lighting Module, Light-Emitting Device, Display Device, Lighting Device, and Electronic Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2023-06-29 US disclosed
US-20230210005-A1 Light-Emitting Element, Compound, Organic Compound, Display Module, Lighting Module, Light-Emitting Device, Display Device, Lighting Device, and Electronic Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2023-06-29 US disclosed
CN-116333001-A Organometallic compound and organic light emitting diode including the same 乐金显示有限公司 2023-06-27 CN disclosed
US-20230129057-A1 Organic Compound, Light-Emitting Device, Electronic Device, Electronic Apparatus, Light-Emitting Apparatus, and Lighting Apparatus SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2023-04-27 US disclosed
US-11600789-B2 Light-emitting element, compound, organic compound, display module, lighting module, light-emitting device, display device, lighting device, and electronic device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2023-03-07 US disclosed
US-20230022400-A1 IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-01-26 US disclosed
US-20130302303-A1 PROTEIN KINASE INHIBITORS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2013-11-14 US disclosed
WO-2009081222-A1 SUBSTITUTED TRICYCLIC PYRIDINE OR PYRIMIDINE VANILLOID RECEPTOR LIGANDS GLENMARK PHARMACEUTICALS, S.A. (US) 2009-07-02 WO disclosed
US-20090143399-A1 Protein Kinase Inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2009-06-04 US disclosed
US-20090099165-A1 Protein Kinase Inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2009-04-16 US disclosed
US-20080051414-A1 Protein Kinase Inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2008-02-28 US disclosed
US-7326712-B2 Substituted tricyclic compounds as protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2008-02-05 US disclosed
US-7312226-B2 Substituted tricyclic compounds as protein kinase inhibitors ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2007-12-25 US disclosed
US-6596726-B1 Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme WARNER LAMBERT COMPANY 2003-07-22 US disclosed
EP-0741711-A1 TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY WARNER-LAMBERT COMPANY (US) 1996-11-13 EP disclosed
WO-1995019970-A1 TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY WARNER-LAMBERT COMPANY (US) 1995-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099165-A1 Protein Kinase Inhibitors CDK2, MAP3K1, MAP3K2 SMN1; SMN2 3186/4885ALDH1A1 2994/4885LMNA 1805/4885
US-20230022400-A1 IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 SMN1; SMN2 4465/4885ALDH1A1 1602/4885LMNA 4793/4885
US-20230129057-A1 Organic Compound, Light-Emitting Device, Electronic Device, Electronic Apparatus, Light-Emitting Apparatus, and Lighting Apparatus TEAD1, GTF2F1, GTF2F2 SMN1; SMN2 4507/4885ALDH1A1 127/4885LMNA 3383/4885
US-11600789-B2 Light-emitting element, compound, organic compound, display module, lighting module, light-emitting device, display device, lighting device, and electronic device TPMT, DPYD, DHODH SMN1; SMN2 2757/4885ALDH1A1 122/4885LMNA 4035/4885
US-20230210005-A1 Light-Emitting Element, Compound, Organic Compound, Display Module, Lighting Module, Light-Emitting Device, Display Device, Lighting Device, and Electronic Device TPMT, DPYD, DHODH SMN1; SMN2 2757/4885ALDH1A1 122/4885LMNA 4035/4885
US-11932638-B2 Ion channel inhibitor compounds for cancer treatment CACNA1E, KCNA1, KCNT1 SMN1; SMN2 3797/4885ALDH1A1 680/4885LMNA 2341/4885
US-20130302303-A1 PROTEIN KINASE INHIBITORS CDK2, MAP3K1, MAP3K2 SMN1; SMN2 3186/4885ALDH1A1 2994/4885LMNA 1805/4885
US-20080051414-A1 Protein Kinase Inhibitors CDK2, MAP3K1, MAP3K2 SMN1; SMN2 3186/4885ALDH1A1 2994/4885LMNA 1805/4885
US-20090143399-A1 Protein Kinase Inhibitors CDK2, MAP3K1, MAP3K2 SMN1; SMN2 3186/4885ALDH1A1 2994/4885LMNA 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.